Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.75 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.62 |
| ▸ | POLB | P06746 | 4/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3471733 | 0.89 | PKM (0.60) | PKMKDM4EPOLBSMN1; SMN2LMNA | |
| SCHEMBL5962801 | 0.88 | PKM (0.58) | PKMKDM4EPOLBSMN1; SMN2LMNA | |
| SCHEMBL5962841 | 0.88 | PKM (0.58) | PKMKDM4EPOLBSMN1; SMN2LMNA | |
| SCHEMBL23412396 | 0.87 | PKM (0.57) | PKMKDM4EPOLBSMN1; SMN2LMNA | |
| SCHEMBL890810 | 0.86 | PKM (1.00) | PKMKDM4EPOLBSMN1; SMN2LMNA | |
| SCHEMBL29033636 | 0.84 | PKM (0.75) | PKMKDM4EPOLBSMN1; SMN2LMNA | |
| SCHEMBL30498928 | 0.84 | PKM (0.75) | PKMKDM4EPOLBSMN1; SMN2LMNA | |
| SCHEMBL29033627 | 0.84 | PKM (0.75) | PKMKDM4EPOLBSMN1; SMN2LMNA | |
| SCHEMBL30498916 | 0.84 | PKM (0.75) | PKMKDM4EPOLBSMN1; SMN2LMNA | |
| SCHEMBL5962774 | 0.83 | PKM (0.56) | PKMKDM4EPOLBSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4069252-B1 | PDIA4 INHIBITORS AND USE THEREOF FOR INHIBITING SS-CELL PATHOGENESIS AND TREATING DIABETES | ACADEMIA SINICA (CN) | 2025-12-10 | — | — | EP | disclosed |
| CN-114761025-B | PDIA4 inhibitors and their use for inhibiting beta cell pathologies and for treating diabetes | 施明哲 | 2024-03-12 | — | — | CN | disclosed |
| US-20230046445-A1 | PDIA4 INHIBITORS AND USE THEREOF FOR INHIBITING ß-CELL PATHOGENESIS AND TREATING DIABETES | ACADEMIA SINICA (TW) | 2023-02-16 | — | — | US | disclosed |
| CN-114761025-A | PDIA4 inhibitor and application thereof in inhibiting beta cell pathology and treating diabetes | 施明哲 | 2022-07-15 | — | — | CN | disclosed |
| WO-2021113062-A1 | PDIA4 INHIBITORS AND USE THEREOF FOR INHIBITING ß-CELL PATHOGENESIS AND TREATING DIABETES | ACADEMIA SINICA (CN) | 2021-06-10 | — | — | WO | disclosed |
| EP-1400510-B1 | CYCLIC DIAMINE COMPOUNDS HAVING FUSED-RING GROUPS | KOWA CO (JP) | 2010-08-18 | — | — | EP | disclosed |
| US-7135473-B2 | Cyclic diamine compound with condensed-ring groups | KOWA CO., LTD. (JP) | 2006-11-14 | — | — | US | disclosed |
| US-7067511-B2 | Pyrrolobenzodiazepines | SPIROGEN LIMITED (GB) | 2006-06-27 | — | — | US | disclosed |
| US-7049311-B1 | Pyrrolbenzodiazepines | SPIROGEN LIMITED (GB) | 2006-05-23 | — | — | US | disclosed |
| EP-1109812-B1 | PYRROLOBENZODIAZEPINES | SPIROGEN LTD (GB) | 2005-05-04 | — | — | EP | disclosed |
| EP-1193270-A2 | Pyrrolobenzodiazepines | Spirogen Limited (GB) | 2002-04-03 | — | — | EP | disclosed |
| CN-1066148-C | Tricyclic benzazepine compounds | MEIJI SEIKA CO (JP) | 2001-05-23 | — | — | CN | disclosed |
| US-6093714-A | AN ANTIALLERGENS FOR TREATMENT AND PREVENTION OF BRONCHIAL ASTHMA, ECZEMA, HIVES, ALLERGIC GASTROINTESTINAL TROUBLES, ALLERGIC RHINITIS, ALLERGIC CONJUNCTIVITIS | MEIJI SEIKA KAISHA, LTD. (JP) | 2000-07-25 | — | — | US | disclosed |
| CN-1190971-A | Tricyclic benzazepine * compounds | MEIJI SEIKA CO (JP) | 1998-08-19 | — | — | CN | disclosed |
| EP-0834512-A1 | TRICYCLIC BENZAZEPINE COMPOUNDS | MEIJI SEIKA KAISHA LTD. (JP) | 1998-04-08 | — | — | EP | disclosed |
| US-4351832-A | 2-(Piperazinyl)-4-pyrimidinamines | AMERICAN HOME PRODUCTS CORPORATION (US) | 1982-09-28 | — | — | US | disclosed |
| US-4333937-A | 2-(Piperazinyl)-4-pyrimioinamines | AMERICAN HOME PRODUCTS CORP. (US) | 1982-06-08 | — | — | US | disclosed |
| EP-0039190-A1 | 2-(1-Piperazinyl)-4-pyrimidinamines and related compounds | AMERICAN HOME PRODUCTS CORPORATION (US) | 1981-11-04 | — | — | EP | disclosed |
| WO-1981003022-A1 | 2-(1-PIPERAZINYL)-4-PYRIMIDINAMINES | AMERICAN HOME PROD (US) | 1981-10-29 | — | — | WO | disclosed |
| EP-0056027-A1 | 2-(1-PIPERAZINYL)-4-PYRIMIDINAMINES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1981-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230046445-A1 | PDIA4 INHIBITORS AND USE THEREOF FOR INHIBITING ß-CELL PATHOGENESIS AND TREATING DIABETES | PDIA4, PDIA6, PDIA5 | PKM 1864/4885KDM4E 1437/4885POLB 4041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.